Micafungin Hikma

Micafungin, the active ingredient in Micafungin Hikma, is an echinocandin antifungal presented as an intravenous solution for use in hospitalized patients with serious fungal infections. It treats invasive candidiasis, esophageal candidiasis, and is employed for prophylaxis in hematopoietic stem cell transplantation as well as Candida peritonitis and intra‑abdominal infections.

GNH USA supplies Micafungin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is used to treat fungal infections that involve the Candida species and related invasive disease pathways. - Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves infection of the esophageal mucosa in immunocompromised patients. - Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection during the transplant conditioning period. - Candida peritonitis and intra‑abdominal infections: used to manage intra‑abdominal Candida infections following surgery or peritonitis.

Micafungin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes. - Headache: mild headache. - Abdominal pain: discomfort in the stomach area. - Elevated liver enzymes: mild increase in ALT/AST.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Anaphylaxis: acute, life‑threatening allergic reaction. - Severe infusion‑related reactions: hypotension, dyspnea, or chest discomfort. - Renal dysfunction: acute kidney injury in rare cases.

When prescribing Micafungin, clinicians should observe several safety considerations. - Liver function monitoring: assess baseline and periodic hepatic enzymes during therapy. - Hypersensitivity assessment: discontinue if signs of rash, angioedema, or anaphylaxis appear. - Hepatic impairment: use with caution and consider dose adjustment in severe liver disease. - Renal function: monitor in patients with severe renal impairment despite limited renal excretion. - Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce micafungin exposure. - Known hypersensitivity to echinocandins: co‑administration should be avoided.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole, voriconazole): may increase micafungin plasma levels, requiring monitoring. - Cyclosporine: concurrent use can raise micafungin concentrations. - Warfarin: potential alteration of anticoagulant effect, monitor INR.